×
About 2,010 results

ALLMedicine™ Hemophilia B Center

Research & Reviews  530 results

Joint Health Study
https://clinicaltrials.gov/ct2/show/NCT03358836

Jun 22nd, 2022 - This is a prospective, non-randomized, controlled study to examine whether or not having a higher trough during prophylactic treatment with clotting factor offers better joint protection than the standard trough of 1% Factor IX (FIX or Factor 9). ...

A proposed algorithm for evaluation and management of pediatric hemophilia patients who...
https://doi.org/10.1002/pbc.29811
Pediatric Blood & Cancer; Kracht MJ, Stein A et. al.

Jun 17th, 2022 - Hemophilia is the deficiency of plasma clotting factor VIII (hemophilia A) or IX (hemophilia B) where management focuses on the prevention and treatment of acute bleeding symptoms and their sequelae. The most concerning risk is for life-threatenin...

Worldwide use of factor IX Padua for hemophilia B gene therapy.
https://doi.org/10.1016/j.ymthe.2022.06.002
Molecular Therapy : the Journal of the American Society O... Samelson-Jones BJ

Jun 16th, 2022 - Worldwide use of factor IX Padua for hemophilia B gene therapy.|2022|Samelson-Jones BJ,|

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
https://clinicaltrials.gov/ct2/show/NCT05421429

Jun 16th, 2022 - This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX...

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
https://clinicaltrials.gov/ct2/show/NCT05145127

May 31st, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...

see more →

Drugs  24 results see all →

Clinicaltrials.gov  83 results

Joint Health Study
https://clinicaltrials.gov/ct2/show/NCT03358836

Jun 22nd, 2022 - This is a prospective, non-randomized, controlled study to examine whether or not having a higher trough during prophylactic treatment with clotting factor offers better joint protection than the standard trough of 1% Factor IX (FIX or Factor 9). ...

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
https://clinicaltrials.gov/ct2/show/NCT05421429

Jun 16th, 2022 - This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX...

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
https://clinicaltrials.gov/ct2/show/NCT05145127

May 31st, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
https://clinicaltrials.gov/ct2/show/NCT03307980

May 26th, 2022 - Evaluation of the long-term level of persistence and potential late or delayed adverse events associated with PF-06838435 (formerly SPK-9001), assessment of the durability of the transgene expression, and determination of the effects of PF-0683843...

Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
https://clinicaltrials.gov/ct2/show/NCT05044845

May 26th, 2022 - This prospective cohort study will use qualitative methods, specifically semi structured interviews to evaluate knowledge, beliefs, and attitude about gene therapy in patients 12 years and older with a diagnosis of moderate and severe hemophilia B...

see more →

News  166 results

Gene Therapy: A 'One and Done' Hemophilia B Treatment?
https://www.medscape.com/viewarticle/968936

Feb 22nd, 2022 - Nearly all patients treated with a one-time gene therapy shot for hemophilia B (HB) were able to discontinue full-dose bleeding prophylaxis, a new industry-funded phase 3 study finds, and annual bleed rates (ABR) fell by 64% after the lead-in peri...

Gene therapy: A ‘one and done’ hemophilia B treatment?
https://www.mdedge.com/hematology-oncology/article/251916/bleeding-disorders/gene-therapy-one-and-done-hemophilia-b
Randy Dotinga

Feb 17th, 2022 - Nearly all patients treated with a one-time gene therapy shot for hemophilia B (HB) were able to discontinue full-dose bleeding prophylaxis, a new industry-funded phase 3 study finds, and annual bleed rates (ABR) fell by 64% after the lead-in peri.

Recombinant factor IX fusion protein benefited untreated patients with hemophilia B
https://www.mdedge.com/hematology-oncology/article/243887/bleeding-disorders/recombinant-factor-ix-fusion-protein-benefited
Mark S. Lesney, PhD

Aug 4th, 2021 - Recombinant factor IX Fc fusion protein was effective, both as prophylaxis and in the treatment of bleeding episodes in previously untreated boys (< 18 years of age) with hemophilia B, according to Beatrice Nolan, MD, of Children’s Health Ireland.

Health Costs Over 25 Times Higher for Patients With Hemophilia B
https://www.medscape.com/viewarticle/951014

May 12th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

Health costs over 25 times higher for hemophilia B patients than controls
https://www.mdedge.com/hematology-oncology/article/239902/bleeding-disorders/health-costs-over-25-times-higher-hemophilia-b
Mark S. Lesney, PhD

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca.

see more →

Patient Education  1 results see all →